A major analysis from the UK Biobank published in the American Journal of Preventive Cardiology has revealed that the cardiovascular risk associated with Lipoprotein(a) [Lp(a)] is not equal across all individuals and is significantly amplified in people with elevated cholesterol levels. The study, involving 127,958 European ancestry participants, sheds light on how Lp(a) interacts with traditional lipid risk factors to influence outcomes such as coronary artery disease (CAD), calcific aortic valve stenosis (CAVS), and ischemic stroke (IS).

Participants had no baseline history of CAD, CAVS, or IS and were followed using multivariable-adjusted Cox regression models. The researchers found that every 10 mg/dL increase in Lp(a) was associated with a 5% higher risk of CAD, a 6% higher risk of CAVS, and a non-significant 1% increase in IS risk.

Statistically significant interactions were observed between Lp(a) and total cholesterol (Total-C), LDL cholesterol (LDL-C), and triglycerides (TG) in relation to the risk of CAD. Individuals with Lp(a) ≥ 50 mg/dL and in the highest quartiles of these lipid markers were at a markedly higher risk of CAD. These interactions suggest that Lp(a)-associated risk is further increased when other lipid levels are high. However, no such association was found for CAVS and IS. The study demonstrated the importance of screening for Lp(a) in individuals with elevated cholesterol.